Literature DB >> 12721104

AT1 receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodeling post-MI.

Quang T Nguyen1, Federico Colombo, Robert Clement, Hugues Gosselin, Jean-Lucien Rouleau, Angelino Calderone.   

Abstract

1. The influence of AII on contractile dysfunction, regulation of the tyrosine kinase-dependent signaling molecule extracellular signal-regulated kinase (ERK), and natriuretic peptide gene expression were examined in the noninfarcted left ventricle (NILV) and right ventricle (RV) during the early phase of remodeling post-myocardial infarct (MI) in the rat. The selective AT(1) receptor antagonist irbesartan was administered <10 h following coronary artery ligation, and rats were killed either at 4-day or 2-week post-MI. 2. At 4 days post-MI, left ventricular systolic pressure (LVSP: sham=125+/-12, MI=91+/-4 mmHg) was decreased, whereas left ventricular end-diastolic pressure (LVEDP: sham=9+/-2, MI=17+/-2 mm Hg), right ventricular systolic (RVSP: sham=26+/-1, MI=34+/-2 mm Hg), and end-diastolic pressures (RVEDP: sham=3+/-0.5, MI=7+/-1 mm Hg) were increased. ERK phosphorylation was significantly elevated in the NILV and RV. 3. Irbesartan (40 mg x kg(-1)/day(-1)) administration did not improve left ventricular function, or suppress increased ERK phosphorylation in the 4-day post-MI rat. By contrast, irbesartan therapy normalized RVSP (MI+irbesartan=25+/-1 mm Hg), RVEDP (MI+irbesartan=3+/-0.3 mm Hg), and reduced ERK1 (MI=3.0+/-0.6, MI+irbesartan=2.0+/-0.3-fold increase), and ERK2 (MI=3.8+/-0.8, MI+irbesartan=2.2+/-0.5-fold increase) phosphorylation. 4. In 2-week post-MI rats, biventricular dysfunction was associated with increased prepro-ANP, and prepro-BNP mRNA expression. Irbesartan therapy normalized RVSP, attenuated RVEDP, and abrogated natriuretic peptide mRNA expression (prepro-ANP; MI=9+/-2, MI+irbesartan=2+/-1-fold increase, prepro-BNP; MI=6+/-2, MI+irbesartan=1+/-1-fold increase), whereas both transcripts remained elevated in the NILV despite the partial attenuation of LVEDP. 5. These data suggest that the therapeutic benefit of irbesartan treatment during the early phase of remodeling post-MI was associated with the preferential amelioration of RV contractile function and phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721104      PMCID: PMC1573810          DOI: 10.1038/sj.bjp.0705212

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung.

Authors:  L Zhao; R al-Tubuly; A Sebkhi; A A Owji; D J Nunez; M R Wilkins
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  Adjunctive drug therapy of acute myocardial infarction--evidence from clinical trials.

Authors:  C H Hennekens; C M Albert; S L Godfried; J M Gaziano; J E Buring
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

3.  Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 receptor in rats.

Authors:  N Makino; T Hata; M Sugano; I M Dixon; T Yanaga
Journal:  J Mol Cell Cardiol       Date:  1996-03       Impact factor: 5.000

Review 4.  Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction.

Authors:  J M Pfeffer; T A Fischer; M A Pfeffer
Journal:  Annu Rev Physiol       Date:  1995       Impact factor: 19.318

5.  Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias.

Authors:  P Bélichard; P Savard; R Cardinal; R Nadeau; H Gosselin; P Paradis; J L Rouleau
Journal:  J Am Coll Cardiol       Date:  1994-02       Impact factor: 24.094

6.  Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed.

Authors:  B J Lipworth; K D Dagg
Journal:  Chest       Date:  1994-05       Impact factor: 9.410

7.  Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression.

Authors:  M Crabos; M Roth; A W Hahn; P Erne
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

9.  Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction.

Authors:  A Hanatani; M Yoshiyama; S Kim; T Omura; I Toda; K Akioka; M Teragaki; K Takeuchi; H Iwao; T Takeda
Journal:  J Mol Cell Cardiol       Date:  1995-09       Impact factor: 5.000

10.  Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content.

Authors:  J F Smits; C van Krimpen; R G Schoemaker; J P Cleutjens; M J Daemen
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

View more
  3 in total

Review 1.  Assessment and treatment of right ventricular failure.

Authors:  Marc A Simon
Journal:  Nat Rev Cardiol       Date:  2013-02-12       Impact factor: 32.419

2.  Antagonism of stromal cell-derived factor-1alpha reduces infarct size and improves ventricular function after myocardial infarction.

Authors:  Cindy Proulx; Viviane El-Helou; Hugues Gosselin; Robert Clement; Marc-Antoine Gillis; Louis Villeneuve; Angelino Calderone
Journal:  Pflugers Arch       Date:  2007-05-23       Impact factor: 3.657

3.  Tamoxifen treatment of myocardial infarcted female rats exacerbates scar formation.

Authors:  Pedro Geraldes; Hugues Gosselin; Jean-François Tanguay; Robert Clément; Angelino Calderone
Journal:  Pflugers Arch       Date:  2007-02-07       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.